Log In
Print
BCIQ
Print
Print this Print this
 

ACC-001, PF-05236806, PF-5236806

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionBeta amyloid-related immunotherapeutic conjugate
Molecular Target Beta amyloid
Mechanism of ActionVaccine
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

Partner

Pfizer Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,500.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today